Suppression of choroidal neovascularization through inhibition of APE1/Ref-1 redox activity

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 7, 2014, Pages 4461-4469

  Li, Yue ^a,b   Liu, Xiuli ^a   Zhou, Tongrong ^a   Kelley, Mark R ^c   Edwards, Paul A ^a   Gao, Hua ^a   Qiao, Xiaoxi ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b Reproductive Center   (China)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiangiogenesis; APE1 Ref 1; Choroidal neovascularization; Redox function; Transcription factors

Indexed keywords

APURINIC ENDONUCLEASE 1; BEVACIZUMAB; E3330; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYASE INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PEPTIDES AND PROTEINS; REDOX EFFECTOR FACTOR 1; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANGIOGENESIS; ANGIOGENESIS ASSAY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL MIGRATION ASSAY; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CHOROID; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ANGIOGRAPHY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; LASER COAGULATION; LUCIFERASE ASSAY; MALE; MOUSE; NICK END LABELING; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RETINA CELL; SUBRETINAL NEOVASCULARIZATION; TUBE FORMATION ASSAY; WESTERN BLOTTING;

ANTIANGIOGENESIS; APE1/REF-1; CHOROIDAL NEOVASCULARIZATION; REDOX FUNCTION; TRANSCRIPTION FACTORS;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BENZOQUINONES; BLOTTING, WESTERN; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINE CCL2; CHOROID; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IN SITU NICK-END LABELING; INTRAVITREAL INJECTIONS; MACACA MULATTA; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; PROPIONATES; STAT3 TRANSCRIPTION FACTOR;

EID: 84904649209     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-14451     Document Type: Article

References (60)

1. Friedman DSOCB, Mũnoz B, Tomany SC, et al. Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004; 122: 564-572.
2. Chiang ARC. Preferred therapies for neovascular age-related macular degeneration. Curr Opin Ophthalmol. 2011; 22: 199-204.
3. CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011; 364: 1897-1908.
4. Rosenfeld PJBD, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med. 2006; 355: 1419-1431.
5. Tufail APP, Egan C, Hykin P, et al. ABC Trial Investigators. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ. 2010; 340: c2459.
6. Campa CCC, Incorvaia C, Sheridan C, et al. Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications. Mediators Inflamm. 2010; 2010: 546826.
7. de Oliveira Dias JRRE, Maia M, Magalhães O Jr, Penha FM, Farah ME. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy. Br J Ophthalmol. 2011; 95: 1631-1637.
8. Read MAWM, Williams AJ, Collins T. NF-kappa B and I kappa B alpha: an inducible regulatory system in endothelial activation. J Exp Med. 1994; 179: 503-512.
9. De Martin RHM, Hofer-Warbinek R, Schmid JA. The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol. 2000; 20: E83-E88.
10. Dryden NHSA, Martin-Almedina S, Hannah RL, et al. The transcription factor Erg controls endothelial cell quiescence by repressing the activity of nuclear factor (NF)-jB p65. J Biol Chem. 2012; 287: 12331-12342.
11. Chen ZHZ. STAT3: a critical transcription activator in angiogenesis. Med Res Rev. 2008; 28: 185-200.
12. Chen SHMD, Lassoued W, Thurston G, Feldman MD, Lee WM. Activated STAT3 is a mediator and biomarker of VEGF endothelial activation. Cancer Biol Ther. 2008; 7: 1994-2003.
13. Jiang AGH, Kelley MR, Qiao X. Inhibition of APE1/Ref-1 redox activity with APX3330 blocks retinal angiogenesis in vitro and in vivo. Vision Res. 2011; 51: 93-100.
14. Kelley MRGM, Fishel ML. APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1. Curr Mol Pharmacol. 2012; 5: 36-53.
15. Zou GMKC, Kabe Y, Handa H, Anders RA, Maitra A. The Ape-1/ Ref-1 redox antagonist E3330 inhibits the growth of tumor endothelium and endothelial progenitor cells: therapeutic implications in tumor angiogenesis. J Cell Physiol. 2009; 219: 209-218.
16. Tell GQF, Tiribelli C, Kelley MR. The many functions of APE1/ Ref-1: not only a DNA repair enzyme. Antioxid Redox Signal. 2009; 11: 601-620.
17. Luo MDS, Jiang A, Reed A, et al. Role of the multifunctional DNA repair and redox signaling protein Ape1/Ref-1 in cancer and endothelial cells: small-molecule inhibition of the redox function of Ape1. Antioxid Redox Signal. 2008; 10: 1853-1867.
18. McNeill DR, Wilson DM III. A dominant-negative form of the major human abasic endonuclease enhances cellular sensitivity to laboratory and clinical DNA-damaging agents. Mol Cancer Res. 2007; 5: 61-70.
19. Evans ARL-FM, Kelley MR. Going APE over ref-1. Mutat Res. 2000; 461: 83-108.
20. Tell GDG, Caldwell D, Kelley MR. The intracellular localization of APE1/Ref-1: more than a passive phenomenon?Antioxid Redox Signal. 2005; 7: 367-384.
21. Bhakat KKMA, Mitra S. Transcriptional regulatory functions of mammalian AP-endonuclease (APE1/Ref-1), an essential multifunctional protein. Antioxid Redox Signal. 2009; 11: 621-638.
22. Xanthoudakis SMG, Curran T. The redox and DNA-repair activities of Ref-1 are encoded by nonoverlapping domains. Proc Natl Acad Sci U S A. 1994; 91: 23-27.
23. Ando KHS, Kabe Y, Ogura Y, et al. A new APE1/Ref-1-dependent pathway leading to reduction of NF-kappaB and AP-1, and activation of their DNA-binding activity. Nucleic Acids Res. 2008; 36: 4327-4336.
24. Xanthoudakis SCT. Identification and characterization of Ref-1, a nuclear protein that facilitates AP-1 DNA-binding activity. EMBO J. 1992; 11: 653-665.
25. Xanthoudakis SMG, Wang F, Pan YC, Curran T. Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme. EMBO J. 1992; 11: 3323-3335.
26. Hiramoto MSN, Sugimoto K, Tang J, et al. Nuclear targeted suppression of NF-jB activity by the novel quinone derivative E3330. J Immunol. 1998; 160: 810-819.
27. Li YLX, Zhou T, Kelley MR, Edwards P, Gao H, Qiao X. Inhibition of APE1/Ref-1 redox activity rescues human retinal pigment epithelial cells from oxidative stress and reduces choroidal neovascularization. Redox Biol. 2014; 2: 485-494.
28. Huang LEAZ, Livingston DM, Bunn HF. Activation of hypoxiainducible transcription factor depends primarily upon redoxsensitive stabilization of its alpha subunit. J Biol Chem. 1996; 271: 32253-32259.
29. Jayaraman LMK, Zhu C, Curran T, Xanthoudakis S, Prives C. Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev. 1997; 11: 558-570.
30. Nyland RLLM, Kelley MR, Borch RF. Design and synthesis of novel quinone inhibitors targeted to the redox function of apurinic/apyrimidinic endonuclease 1/redox enhancing factor-1 (Ape1/ref-1). J Med Chem. 2010; 53: 1200-1210.
31. Zou GMMA. Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration. Mol Cancer Ther. 2008; 7: 2012-2021.
32. Zou GMLM, Reed A, Kelley MR, Yoder MC. Ape1 regulates hematopoietic differentiation of embryonic stem cells through its redox functional domain. Blood. 2007; 109: 1917-1922.
33. Shimizu NSK, Tang J, Nishi T, et al. High-performance affinity beads for identifying drug receptors. Nat Biotechnol. 2000; 18: 877-881.
34. Curtis CDTD, Ziegler YS, Sarkeshik A, Yates JR, Nardulli AM. Apurinic/apyrimidinic endonuclease 1 alters estrogen receptor activity and estrogen-responsive gene expression. Mol Endocrinol. 2009; 23: 1346-1359.
35. Hu WJA, Liang J, Meng H, Chang B, Gao H, Qiao X. Expression of VLDLR in the retina and evolution of subretinal neovascularization in the knockout mouse model's retinal angiomatous proliferation. Invest Ophthalmol Vis Sci. 2008; 49: 407-415.
36. Jiang AHW, Meng H, Gao H, Qiao X. Loss of VLDL receptor activates retinal vascular endothelial cells and promotes angiogenesis. Invest Ophthalmol Vis Sci. 2009; 50: 844-850.
37. Klemke RLCS, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA. Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol. 1997; 137: 481-492.
38. Mullins RFGM, Skeie JM. Glycoconjugates of choroidal neovascular membranes in age-related macular degeneration. Mol Vis. 2005; 509-517.
39. Chiarini LBFF, Petrs-Silva H, Linden R. Evidence that the bifunctional redox factor/AP endonuclease Ref-1 is an antiapoptotic protein associated with differentiation in the developing retina. Cell Death Differ. 2000; 7: 272-281.
40. Brown DMKP, Michels M, Soubrane G, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular agerelated macular degeneration. N Engl J Med. 2006; 355: 1432-1444.
41. Brown DMMM, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009; 116: 57-65. e55.
42. Spaide RF. Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol. 2006; 141: 149-156.
43. Sengupta NAA, Caballero S, Chang KH, et al. Paracrine modulation of CXCR4 by IGF-1 and VEGF: implications for choroidal neovascularization. Invest Ophthalmol Vis Sci. 2010; 51: 2697-2704.
44. Nagineni CNKV, William A, Detrick B, Hooks JJ. Regulation of VEGF expression in human retinal cells by cytokines: implications for the role of inflammation in age-related macular degeneration. J Cell Physiol. 2012; 227: 116-126.
45. Xanthoudakis SCT. Identification and characterization of Ref-1, a nuclear protein that facilitates AP-1 DNA-binding activity. EMBO J. 1992; 11: 653-665.
46. Dejana E. Endothelial cell-cell junctions: happy together. Nat Rev Mol Cell Biol. 2004; 5: 261-270.
47. Jeon BHGG, Park YC, Qi B, et al. Apurinic/apyrimidinic endonuclease 1 regulates endothelial NO production and vascular tone. Circ Res. 2004; 95: 902-910.
48. Gupta SCSC, Reuter S, Aggarwal BB. Inhibiting NF-jB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta. 2010; 1799: 775-787.
49. Nagineni CNKV, William A, Detrick B, Hooks JJ. Regulation of VEGF expression in human retinal cells by cytokines: implications for the role of inflammation in age-related macular degeneration. J Cell Physiol. 2012; 227: 116-126.
50. Jougasaki MIT, Takenoshita Y, Setoguchi M. Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells. Br J Pharmacol. 2010; 159: 1294-1303.
51. Cardoso AAJY, Luo M, Reed AM, et al. APE1/Ref-1 regulates STAT3 transcriptional activity and APE1/Ref-1-STAT3 dualtargeting effectively inhibits pancreatic cancer cell survival. PLoS One. 2012; 7: e47462.
52. Toledano MBLW. Modulation of transcription factor NF-kappa B binding activity by oxidation-reduction in vitro. Proc Natl Acad Sci U S A. 1991; 88: 4328-4332.
53. Matthews JRWN, Virelizier JL, Yodoi J, Hay RT. Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res. 1992; 20: 3821-3830.
54. Li LCS, Evans EL, Shaw PE. Modulation of gene expression and tumor cell growth by redox modification of STAT3. Cancer Res. 2010; 70: 8222-8232.
55. Wang XCJC, Allen JB, Roberts WL, Jaffe GJ. Suppression of NFkappaB-dependent proinflammatory gene expression in human RPE cells by a proteasome inhibitor. Invest Ophthalmol Vis Sci. 1999; 40: 477-486.
56. Grossniklaus HELJ, Wallace TM, Dithmar S, et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis. 2002; 119-126.
57. Suzuki MTM, Itabe H, Du ZJ, et al. Chronic photo-oxidative stress and subsequent MCP-1 activation as causative factors for age-related macular degeneration. J Cell Sci. 2012; 125: 2407-2415.
58. Raoul WAC, Camelo S, Guillonneau X, Feumi C, Combadìere C, Sennlaub F. CCL2/CCR2 and CX3CL1/CX3CR1 chemokine axes and their possible involvement in age-related macular degeneration. J Neuroinflammation. 2010; 7: 87.
59. Yamada KSE, Itaya M, Yamasaki S, Ogura Y. Inhibition of laserinduced choroidal neovascularization by atorvastatin by downregulation of monocyte chemotactic protein-1 synthesis in mice. Invest Ophthalmol Vis Sci. 2007; 48: 1839-1843.
60. Tomida DNK, Kataoka K, Yasuma TR, et al. Suppression of choroidal neovascularization and quantitative and qualitative inhibition of VEGF and CCL2 by heparin. Invest Ophthalmol Vis Sci. 2011; 52: 3193-3199.